Revance Therapeutics (RVNC) Earnings Date, Estimates & Call Transcripts $3.65 0.00 (0.00%) As of 02/6/2025 Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Revance Therapeutics Earnings Summary Upcoming Q4 Earnings DateMay. 7After Market ClosesEstimatedConsensus EPS (Nov. 7) -$0.35 Actual EPS (Nov. 7) -$0.37 Missed By -$0.02 Actual Revenue (Nov. 7) $59.88MRevance Therapeutics issued Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.37, which missed the consensus estimate of -$0.35 by $0.02. Quarterly revenue was reported to be $59.88 million, below analyst estimates of $67.73 million. With a trailing EPS of -$1.93, Revance Therapeutics' earnings are expected to grow next year, from ($1.57) to ($1.08) per share. Q3 2024 Earnings ResourcesQ3 2024 Earnings Report Press Release (8-K) Quarterly Report (10-Q)RVNC Upcoming EarningsRevance Therapeutics' next earnings date is estimated for Wednesday, May 7, 2025, based on past reporting schedules. Powered by Get Revance Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revance Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRVNC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RVNC Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Revance Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20251-$0.49-$0.49-$0.49Q2 20251-$0.26-$0.26-$0.26Q3 20251-$0.26-$0.26-$0.26Q4 20251-$0.20-$0.20-$0.20 Revance Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/7/2025(Estimated)--------11/7/2024Q3 2024-$0.35-$0.37 -$0.02-$0.37$67.73M$59.88M8/8/2024Q2 2024-$0.48-$0.36+$0.12-$0.36$66.30M$65.39M5/9/2024Q1 2024-$0.66-$0.54+$0.12-$0.50$55.64M$51.94M2/28/2024Q4 2023-$0.79-$0.62+$0.17-$0.62$64.02M$69.80M11/8/2023Q3 2023-$1.02-$0.74+$0.28$0.15$58.49M$56.78M8/8/2023Q2 2023-$0.72-$0.80 -$0.08-$0.80$58.71M$58.13M5/9/2023Q1 2023-$0.75-$0.74+$0.01-$0.74$46.21M$49.33M Revance Therapeutics Earnings - Frequently Asked Questions When is Revance Therapeutics's earnings date? Revance Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 7th, 2025 based off last year's report dates. Learn more on RVNC's earnings history. Did Revance Therapeutics beat their earnings estimates last quarter? In the previous quarter, Revance Therapeutics (NASDAQ:RVNC) missed the analysts' consensus estimate of ($0.35) by $0.02 with a reported earnings per share (EPS) of ($0.37). Learn more on analysts' earnings estimate vs. RVNC's actual earnings. How much revenue does Revance Therapeutics generate each year? Revance Therapeutics (NASDAQ:RVNC) has a recorded annual revenue of $234.04 million. How much profit does Revance Therapeutics generate each year? Revance Therapeutics (NASDAQ:RVNC) has a recorded net income of -$323.99 million. RVNC has generated -$1.93 earnings per share over the last four quarters. What is Revance Therapeutics's EPS forecast for next year? Revance Therapeutics's earnings are expected to grow from ($1.57) per share to ($1.08) per share in the next year. More Earnings Resources from MarketBeat Related Companies Vera Therapeutics Earnings ARS Pharmaceuticals Earnings Structure Therapeutics Earnings Ocular Therapeutix Earnings Dyne Therapeutics Earnings Ardelyx Earnings Calliditas Therapeutics AB (publ) Earnings Iovance Biotherapeutics Earnings Amphastar Pharmaceuticals Earnings Syndax Pharmaceuticals Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's EarningsAmazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan This page (NASDAQ:RVNC) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RVNC Stock Free RVNC Stock Alerts